Acurx Pharmaceuticals Inc (ACXP) Stock Price, Quote & News

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 533 1469

Website: www.acurxpharma.com

Address:

259 Liberty Avenue, Staten Island, United States

Joby099 Mar. 15 at 12:57 AM

$ACXP

0 · Reply

KnightDracula Mar. 15 at 12:55 AM

Cyber Security tickers are a must watch after the white house news that came out on Friday. Make sure you have ticker IPM on watch. ✅ IPM makes the perfect sense to be in now before crowd finds it and takes off. IPM: ✅They never diluted since 2021 ✅ 5M float ✅Catalysts lined up ✅global cybersecurity market was $272B in 2025 and is projected to reach ~$500B by 2030 ✅ROTH Conference (Mar 22–24) I believe IPM is the best low float cyber security play. $SCNX $AMCI $ACXP $MRNO hot ones.

0 · Reply

Joby099 Mar. 14 at 3:49 PM

$ACXP

0 · Reply

MomentumChasers Mar. 14 at 1:04 AM

@ElevenXProfits a good one to Follow, He's been calling some banger trades 💯 insane week on $ACXP $RIME $AZI $ATPC

0 · Reply

Joby099 Mar. 13 at 11:30 PM

$ACXP

0 · Reply

mhaven2020 Mar. 13 at 8:43 PM

$ACXP wow! Should have had the stop loss set! Thankfully, I'm not too heavy yet, i will probably buy more Monday. Level 2 AH... I'll dig in and make a video about this little gem. See it on YouTube when it drops. Check out our website and follow for more !

0 · Reply

SPX_Options_Trader Mar. 13 at 8:29 PM

$ACXP Also, I wonder if they try to run it hard next week, then get a offering that then tanks it...

1 · Reply

SPX_Options_Trader Mar. 13 at 8:26 PM

$ACXP Best case from here: It consolidates for a few days above roughly 3.80 to 4.00, then makes another push toward: 4.35 to 4.40 then 5.05 to 5.10 stretch zone 5.80 to 6.00+

0 · Reply

Proecadguy Mar. 13 at 8:07 PM

$ACXP Lets go

1 · Reply

Mantraset3 Mar. 13 at 8:04 PM

$ACXP a nice big ol’ 💩 dump 👀 here 🗑️

0 · Reply

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript

Mar 13, 2026, 7:01 AM EDT - 1 day ago

Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

Mar 11, 2026, 2:45 PM EDT - 3 days ago

Why Is Acurx Pharmaceuticals Stock Up Over 105% Today?

Mar 9, 2026, 8:01 AM EDT - 5 days ago

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection

Feb 16, 2026, 8:01 AM EST - 26 days ago

Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

Feb 2, 2026, 8:00 AM EST - 5 weeks ago

USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

Nov 18, 2025, 8:00 AM EST - 4 months ago

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Nov 12, 2025, 10:11 AM EST - 4 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:01 AM EST - 4 months ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

Nov 10, 2025, 8:00 AM EST - 4 months ago

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

Oct 28, 2025, 8:00 AM EDT - 4 months ago

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

Oct 27, 2025, 8:00 AM EDT - 4 months ago

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

Oct 9, 2025, 7:30 AM EDT - 5 months ago

Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Sep 30, 2025, 7:30 AM EDT - 5 months ago

Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection

Sep 3, 2025, 7:01 AM EDT - 6 months ago

Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules

Aug 12, 2025, 10:13 AM EDT - 7 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:01 AM EDT - 7 months ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

Jul 31, 2025, 9:25 AM EDT - 8 months ago

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Jul 24, 2025, 7:01 AM EDT - 8 months ago

Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update

Jun 17, 2025, 9:47 PM EDT - 9 months ago

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Jun 17, 2025, 7:01 AM EDT - 9 months ago

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Jun 9, 2025, 7:30 AM EDT - 9 months ago

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

May 13, 2025, 1:59 PM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:01 AM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 11 months ago

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Apr 28, 2025, 7:30 AM EDT - 11 months ago

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Apr 17, 2025, 7:30 AM EDT - 11 months ago

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Mar 18, 2025, 9:44 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 10, 2025, 4:30 PM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Mar 7, 2025, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Mar 3, 2025, 8:00 AM EST - 1 year ago

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Feb 28, 2025, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Feb 24, 2025, 8:00 AM EST - 1 year ago

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Feb 19, 2025, 8:00 AM EST - 1 year ago

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Jan 7, 2025, 5:00 PM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 5:35 PM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 8:30 AM EST - 1 year ago

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Dec 11, 2024, 11:00 AM EST - 1 year ago

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Dec 9, 2024, 8:00 AM EST - 1 year ago

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Nov 20, 2024, 10:53 AM EST - 1 year ago

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

Nov 20, 2024, 7:01 AM EST - 1 year ago

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 7:00 AM EST - 1 year ago

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Nov 13, 2024, 11:43 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:00 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Oct 21, 2024, 10:07 AM EDT - 1 year ago

Acurx Ready To Expand Pipeline With Anthrax Treatment

Oct 21, 2024, 7:00 AM EDT - 1 year ago

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Oct 14, 2024, 1:00 PM EDT - 1 year ago

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support

Joby099 Mar. 15 at 12:57 AM

$ACXP

0 · Reply

KnightDracula Mar. 15 at 12:55 AM

0 · Reply

Joby099 Mar. 14 at 3:49 PM

$ACXP

0 · Reply

MomentumChasers Mar. 14 at 1:04 AM

@ElevenXProfits a good one to Follow, He's been calling some banger trades 💯 insane week on $ACXP $RIME $AZI $ATPC

0 · Reply

Joby099 Mar. 13 at 11:30 PM

$ACXP

0 · Reply

mhaven2020 Mar. 13 at 8:43 PM

0 · Reply

SPX_Options_Trader Mar. 13 at 8:29 PM

$ACXP Also, I wonder if they try to run it hard next week, then get a offering that then tanks it...

1 · Reply

SPX_Options_Trader Mar. 13 at 8:26 PM

$ACXP Best case from here: It consolidates for a few days above roughly 3.80 to 4.00, then makes another push toward: 4.35 to 4.40 then 5.05 to 5.10 stretch zone 5.80 to 6.00+

0 · Reply

Proecadguy Mar. 13 at 8:07 PM

$ACXP Lets go

1 · Reply

Mantraset3 Mar. 13 at 8:04 PM

$ACXP a nice big ol’ 💩 dump 👀 here 🗑️

0 · Reply

lucjen23 Mar. 13 at 8:00 PM

$ACXP low attention biotech coil and this gets spicy if quiet accumulation turns louder

0 · Reply

SPX_Options_Trader Mar. 13 at 7:50 PM

$ACXP - @BlitzTradez inverse Head N Shoulders forming. It wants higher.

1 · Reply

SPX_Options_Trader Mar. 13 at 7:47 PM

$ACXP Dead cat bounce can even see 30-60% bounce.

0 · Reply

SPX_Options_Trader Mar. 13 at 7:46 PM

$ACXP $4.22, $4.55, $4.8, then $5++

0 · Reply

BlitzTradez Mar. 13 at 7:46 PM

$ACXP are we seeing a cup and handle form?? LLKV

0 · Reply

Donniechen12345 Mar. 13 at 7:45 PM

$ACXP that line is at $4 wont go pass $4.10 … will dip back to $3.25 :( next week

0 · Reply

Donniechen12345 Mar. 13 at 7:42 PM

$ACXP wont break pass $4.05 , dead cat bounce !!! get out !!!!

0 · Reply

eatsleeptrades Mar. 13 at 7:34 PM

$ACXP who added with me? Next big move to come

0 · Reply

SPX_Options_Trader Mar. 13 at 7:33 PM

$ACXP clean bounce off the 100EMA. $4, the $5++ with this incoming volume.

0 · Reply

Donniechen12345 Mar. 13 at 7:21 PM

$ACXP dam algo lol

2 · Reply

Donniechen12345 Mar. 13 at 7:17 PM

$ACXP Fake punp heading back down lol

0 · Reply

Donniechen12345 Mar. 13 at 7:10 PM

$ACXP smh another fake pump just to drop another 20% ….,,,, dont fall for this again lol will short more here $$$$

0 · Reply

Market Cap	9.88M
Revenue (ttm)	0.00
Net Income (ttm)	-14.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,863,300
Avg Vol	3,276,556
Day's Range	N/A - N/A
Shares Out	2.55M
Stochastic %K	51%
Beta	-1.16
Analysts	Strong Sell
Price Target	$18.67